middle.news
Actinogen Advances Alzheimer’s Trials, Eyes 2026 Breakthroughs
10:50pm on Friday 29th of August, 2025 AEST
•
Healthcare
Read Story
Actinogen Advances Alzheimer’s Trials, Eyes 2026 Breakthroughs
10:50pm on Friday 29th of August, 2025 AEST
Key Points
XanaMIA phase 2b/3 Alzheimer’s trial surpasses 100 participants
Interim XanaMIA results due January 2026; final data expected Q4 2026
Completed XanaCIDD phase 2a depression trial with promising outcomes
Secured $11.1m capital raising plus $9m R&D tax rebate and $13.8m funding facility
Read Story
middle.
Tap to Read
Tap the card to read the full analysis
about
ACTINOGEN MEDICAL (ASX:ACW)
OPEN ARTICLE